Latest Contract Manufacturing News

Page 2 of 11
BLS Pharmaceuticals has opened FY27 with record quarterly revenue, positive operating cash flow and reaffirmed full-year guidance. The report contains conflicting Q1 revenue figures of $26.7 million and $27.5 million, while its Scotland expansion remains subject to regulatory approval.
Victor Sage
Victor Sage
15 Oct 2026
ReNerve has received supportive FDA feedback on the preclinical and testing pathway for its NervAlign Nerve Guide Matrix. The guidance sharpens the route towards a US submission, but does not amount to clearance and leaves the submission timetable open.
Victor Sage
Victor Sage
14 Oct 2026
Mesoblast has reported a sharp commercial step-up in FY2026, with Ryoncil generating US$115.2 million in net sales and total revenue reaching US$120.3 million. The company has also completed treatment in its 350-patient back-pain trial and refinanced its debt, but remains loss-making and expects to need more capital beyond the next 12 months.
Ada Torres
Ada Torres
12 Oct 2026
Wide Open Agriculture has completed a study for a proposed 10,000-tonne-per-year lupin protein facility with indicative annual revenue of A$240 million to A$295 million. The project remains unfunded, unapproved and years from production, leaving contract manufacturing as the immediate test of the company’s strategy.
Victor Sage
Victor Sage
6 Oct 2026
Pure Foods Tasmania has warned of a material uncertainty over its ability to continue as a going concern after reporting an $8.6 million FY2026 loss, negative cash and a breach of its Commonwealth Bank covenant. The company expects its existing funding facilities to fall short from approximately February 2027, with further equity funding still uncommitted.
Victor Sage
Victor Sage
30 Sept 2026
Structural Monitoring Systems (ASX:SMN) delivered record FY26 revenue, a sharp lift in profit and $6.0 million of free cash flow as its avionics business outpaced contract manufacturing. The balance sheet is now free of bank debt, but the next leg of the story still depends on FAA approvals and converting CVM technology into commercial revenue.
Victor Sage
Victor Sage
29 Sept 2026
AdAlta has secured a formal US FDA pre-IND meeting for EW-001, moving its mesothelioma CAR-T therapy into a critical regulatory review. The November meeting will test the company’s Australian manufacturing, remaining studies and proposed Phase 1 trial before the more expensive stages of development begin.
Ada Torres
Ada Torres
23 Sept 2026
AdAlta says a 10-year, up to US$120 million agreement between manufacturing partner Oribiotech and an undisclosed commercial-stage biopharmaceutical company validates its choice of IRO automation for future cellular immunotherapies. The deal does not create direct revenue for AdAlta, and its lead asset EW-001 will continue with a separate manufacturing process.
Ada Torres
Ada Torres
18 Sept 2026
Codan Limited (ASX:CDA) has entered FY27 with record revenue, profit and a sharply larger Communications orderbook, while targeting approximately 20% Communications revenue growth. The forecast is conditional on supply-chain capacity as demand for unmanned systems and new gold detectors accelerates.
Sophie Babbage
Sophie Babbage
17 Sept 2026
Wide Open Agriculture has signed three additional non-binding framework agreements with prospective contract manufacturers in Vietnam, India and Indonesia, bringing its shortlist to four. The agreements protect WOA’s lupin intellectual property while technical and commercial feasibility work begins, but stop well short of securing production or revenue.
Victor Sage
Victor Sage
14 Sept 2026
Bubs Australia has secured permanent US FDA authorisation for three infant formula products, removing a regulatory barrier in the company’s largest market. The approval supports possible portfolio expansion and contract manufacturing, but the presentation contains no new earnings guidance or quantified financial benefit.
Victor Sage
Victor Sage
10 Sept 2026
OncoSil Medical has moved closer to local production after contract manufacturer Cyclotek secured ISO 13485 certification for its quality management system. Production at the Macquarie Park facility remains targeted for the end of 2Q FY27, subject to further regulatory approval.
Victor Sage
Victor Sage
9 Sept 2026

Browse the archive

Full archive